Patents by Inventor Tobias Brodmann

Tobias Brodmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MEDICAL USE OF COMPOUND III
    Publication number: 20210130362
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Application
    Filed: January 11, 2021
    Publication date: May 6, 2021
    Inventors: Michael Steven SAND, Holger ROSENBROCK, Riccardo GIOVANNINI, Masashi ADACHI, Bodo BETZEMEIER, Tobias BRODMANN, Takayuki KAMATA, Yohei KAWABATA, Masanori ITO, Daniel MARCKART, Manabu NAKATANI, Ulrike WERTHMANN
  • Medical use of compound III
    Patent number: 10919898
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Grant
    Filed: February 21, 2018
    Date of Patent: February 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Michael Steven Sand, Holger Rosenbrock, Riccardo Giovannini, Masashi Adachi, Bodo Betzemeier, Tobias Brodmann, Takayuki Kamata, Yohei Kawabata, Masanori Ito, Daniel Marckart, Manabu Nakatani, Ulrike Werthmann
  • Medical Use of Compound III
    Publication number: 20180237445
    Abstract: The present invention relates to compound III and its use for treatment and/or prevention of diseases of the schizophrenia spectrum and other psychotic disorders, first episodes of these diseases such as first episode of psychosis (FEP), relapses of these diseases such as reduction of relapse in patients with schizophrenia (REX). The invention also relates to polymorphs of compound III, and pharmaceutical compositions comprising compound III and/or its polymorphs.
    Type: Application
    Filed: February 21, 2018
    Publication date: August 23, 2018
    Inventors: Michael Steven SAND, Holger ROSENBROCK, Riccardo GIOVANNINI, Masashi ADACHI, Bodo BETZEMEIER, Tobias BRODMANN, Takayuki KAMATA, Yohei KAWABATA, Masanori ITO, Daniel MARCKART, Manabu NAKATANI, Ulrike WERTHMANN
  • Method for producing intermediates for the production of novel macrocycles that are inhibitors of the proteasomic degradation of p27, such as argyrin and derivatives thereof, and uses of said macrocycles
    Patent number: 9458200
    Abstract: The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.
    Type: Grant
    Filed: June 23, 2009
    Date of Patent: October 4, 2016
    Assignees: Gottfried Wilhelm Leibniz Universität Hannover, Medizinische Hochschule Hannover, Helmholtz-Zentrum für Infektionsforschung GmbH
    Inventors: Markus Kalesse, Nisar Malek, Ronald Frank, Tobias Brodmann, Leila Bülow, Andreas Rentsch, Anna-Katharina Girbig, Ulrike Eggert
  • Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles
    Publication number: 20110311564
    Abstract: The present invention relates to the use of particular macrocycles that are inhibitors of the proteasomic degradation of p27, in particular argyrin and derivatives thereof, for a treatment in a variety of conditions, such as the induction of immunotolerance, autoimmune diseases, bacterial infections, and proliferative diseases, such as cancers.
    Type: Application
    Filed: June 23, 2009
    Publication date: December 22, 2011
    Inventors: Markus Kalesse, Leíla Bülow, Andreas Rentsch, Anna-Katharina Girbig, Ulrike Eggert, Nisar Malek, Ronald Frank, Tobias Brodmann